We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

VEDA LAB

VEDALAB focuses on the development, production and marketing of in vitro immunodiagnostic reagents and instruments. I... read more Featured Products: More products

Download Mobile App





Vedalab Exhibits Rapid Diagnostic Tests

By LabMedica International staff writers
Posted on 11 Nov 2024

Vedalab (Cerisé, France) is showcasing its wide range of rapid diagnostic tests at the MEDICA exhibition from November 11th to 14th, 2024 being held in Dusseldorf, Germany. More...

Vedalab offers a wide range of immunochromatographic rapid tests which are being highlighted at the trade fair. This includes the new Vitamin D-CHECK-1 immunochromatographic rapid test for the quantitative determination of Vitamin D in plasma or serum samples and the Toxo IgG-CHECK-1 immunochromatographic rapid test for the qualitative detection of IgG antibodies to Toxoplasma gondii in whole blood, plasma or serum samples. Vedalab’s quantitative rapid tests are designed for use on its EASY READER+ instrument showcased at MEDICA 2024. This POC reader enables quantitative measurements from finger-prick whole blood samples using rapid lateral flow tests. The instrument includes the most advanced and up-to-date technologies such as touch screen, enhanced memory, and internet upgrading. The EASY READER+ and quantitative rapid tests are designed for healthcare professionals, for use in physician’s offices, clinical laboratories, and online pharmacies, and for consumers through organizations that provide diagnostic information.

Vedalab’s EASY READER+ and quantitative rapid tests are widely used as screening tools for various medical conditions and diseases. Vedalab is also highlighting its range of immunochromatographic rapid tests for the quantitative detection of AFP (alpha-fetoprotein), beta chain specific hCG (human chorionic gonadotrophin), C-peptide, CA 125 (ovarian cancer antigen), Cancer Antigen 15-3 (CA 15-3), Cancer Antigen 19-9 (CA 19-9), Calprotectin, CEA (carcinoembryonic antigen), Creatine Kinase MB isoenzyme, Cortisol, C-reactive protein, and D-DIMER in whole blood, serum, urine or plasma samples. These tests generate accurate, rapid, and cost-effective diagnostic information for acute and chronic conditions affecting men's and women's health at various stages of life.

Related Links:
Vedalab


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.